The Top 50 Firm acquired Machen McChesney and its sister company, FocusPay Solutions, continuing its wave of dealmaking and expanding its footprint in the Southeast.
The proposed regs apply to taxpayers who sell or exchange farmland to qualified farmers and elect to pay the tax on the gain in four equal annual installments.
Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.
The recent FDA approval of Fayuvi for a rare, childhood neurodegenerative disease was “particularly special” for Ultragenyx CEO Emil Kakkis. It could also, along with an August nod for another gene therapy, help offset recent challenges brought on by two asset failures.